BULLETIN OF INFORMATICS

BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

REINFORCEMENT LEARNING IN CARDIOVASCULAR THERAPY PROTOCOL: A NEW PERSPECTIVE

Hira Zainab[1], Roman Khan[2], Arbaz Haider Khan[3], Hafiz Khawar Hussain[4]

[1]Department of Information Technology Institute: American National University

[2]Lewis University Chicago

[3]University of Punjab

[4]DePaul University Chicago, Illinois

[1]hira.zainab72@gmail.com [2]romankhan@lewisu.edu [3]arbazhaiderkhan15@gmail.com,
[4]Hhussa14@depaul.edu

Abstract

Two examples of how RL, a technique in cardiovascular therapy that UK scientists are studying to enhance existence and lessen its number of negative effects, could advance therapy plans and momentous decision-making. In this paper, an attempt is made to look at the application of RL in cardiovascular medicine and how and in what ways it can be used to define the need for the treatment plan molding and drug dosage optimization as well as the patient outcome predictions based on actual-time data. Moreover, application of RL in Cardiovascular Disordered Increases patient rehabilitation utilizing other AI approaches like Computer vision and Predictive Analytics. However, there is a list of challenges that need to be addressed before this technology may be implemented in clinical practice such as data quality, interpretability and integration with the existing workflow. To ensure that the use of AI in healthcare is safe and permits fairness in its application some of the ethical issues include: informed permission, data privacy, and regulation as well as accountability for bias in algorithms. Potential future possibilities of RL in cardiovascular therapy include higher patient benefits, real-life adjustment of treatments plans, and advancements in algorithm design. Making sense of RL's potential and creating the environment to close the gap between the individual patient's, efficient, and equitable cardiovascular treatment will involve overcoming its ethical and technological challenges.

Key words

Cardiovascular treatment, decision-making in operation, Deep learning and AI, risk assessment, dosing, medication effect, potential for algorithms to be prejudiced, transparent, Problems in Ethics, privacy of patient data, reinforcement learning, healthcare improvement, dynamic treatment, artificial intelligence, clinical use

INTRODUCTION

In the world, CVDs remain the leading cause of morbidity and mortality, which put tremendous pressure on healthcare facilities. Given that cardiovascular disease is now experienced more due to increased elderly people, lack of exercise, and increases in obesity, there is a higher than ever need for cost-effective methods of treatment. Because any type of cardiovascular therapy, which might entail drug management, surgery, as well as lifestyle modifications particular type of therapy must be individualized and adjusted to the patient [1]. However, given complexities of human physiology, variations in patient response and limitations inherent to the decision making process in clinical medicine present challenges to more traditional ways of developing and implementing treatments/management plans.

In this regard, than machine learning (ML), and more especially reinforcement learning (RL) have emerged as important tools that can enhance therapeutic models. It also proves that they have an opportunity to enhance the tactics of interactions with patients and outcomes of such interactions [2]. Reinforcement learning is a field of AI in which an agent learns decision-making capabilities to presumably survive or achieve particular objectives to collect maximum cumulative pay offs while interacting with the environment. The fact that this method is oriented on decision-making and learning in time from previous experience, differentiates it from other machine learning methods, and so it is very suitable for long-term dynamic decisions as in cardiovascular therapy or healthcare. RL can be rather useful within cardiovascular medicine because it allows rich models of treatment that evolve with moments when new data can be included. RL adapts therapy management and makes necessary modifications in response to current patient reactions, treatment progress, and new input data unlike rule-based systems that apply pre-specified rules or set decision trees [3]. This dynamic adaptability is considerably crucial in cardiovascular diseases because in these diseases, patients respond differently to the treatment and the results characteristically depend on numbers of factors, which can be the life style decisions, genetic profiles and other medical conditions, etc.

In settings as diverse as drug dosing, and the timing of medication intake to handling complex, concurrent cardiovascular disorders such as hypertension, arrhythmias, and heart failure the notion of using RL to improve cardiovascular therapy regimens is therefore a relatively nascent area of research. Another potential that RL may bring to enhance clinical workflows is that it supplies physicians with data-aided findings which can be helpful both in decision-making processes and in reducing human mistakes. Moreover, earlier and more effective actions, and, finally, improved long-term outcomes could be expected as a result of its ability to respond to the changes in a patient's state in RL systems [4]. However, there are several challenges relating to the application of RL into cardiovascular treatment protocols. For instance, owing to the many complexities associated with the data such as patient data, privacy issues and missing records it could become extremely difficult to obtain the large, high quality datasets required for training the RL models in a medical context. Several ethical and pragmatic concerns emerge while delivering HL, including anomaly to past data, decision-making transparency, and human intervention, also need to be addressed while designing the RL systems. It is clear that several major barriers need to be addressed before RL can be employed clinically in cardiovascular therapy [5]. These are the need to conduct validation studies, permission from the regulatory authorities and incorporation of the current medical systems. Therefore the aim of this paper will be to discuss potential application of RL, benefits that may result from employing RL and challenges of employing RL in cardiovascular therapy procedures. Understanding how this novel method could revolutionize the treatment of cardiovascular diseases may be achieved by examining the state-of-art in Reinforcement Learning research in cardiovascular diseases.

REINFORCEMENT LEARNING FUNDAMENTALS

Reinforcement learning (RL) is a subfield of machine learning focused on identifying how such an agent should behave to obtain the highest sum of reward in that context. This is due to its basis on Behavioral psychology that asserts that learning occurs through interacting with the environment and as a result receiving positive or negative reings. The essential idea of RL as opposed to other types of ML, including supervised and unsupervised learning is that it focuses more on the process of making decisions step by step rather than trying to make sense of a given dataset or learn from labeled examples [6].

Essential Ideas in Reinforcement Learning: The agent, the environment, the actions, the states and the rewards are categories of reinforcement learning systems. The reinforcement learning framework comprises of an agent as the participant who continuously observes the environment to make decisions and receive consequential outcomes. Within the medical profession the agent could be an algorithm designed to provide or change the direction of a patient's therapy [7]. The world outside that which in this context forms the area where the agent operates with is called the environment. In the healthcare industry, the environment may encompass the human body, the simulation of a patient model, or a system that responds to actions taken by the agent like administering therapy or changing drugs [8].

States: Both the affiliate itself and the environment as_on the one hand, denotes the specific conditions, or rather states that exist in the environment at a certain point in time. Companies could represent a patient's temperature, blood pressure, blood test results, and sometimes even development of an illness for medical purposes.

Actions: The options are available to the agent in relation to altering the environment. Examples of such acts that require knowledge and skill in cardiovascular therapy include decisions concerning the dose of a particular medication, the timing of an intervention, and any alterations of the course of treatment that may be undertaken because of the patient's reaction to the proposed therapies [9].

Rewards: The count expressed as a number value of the agent's feedback after an activity. In reinforcement learning, the total amount of reward over time is sought to be optimized [10]. In the case of health care, incentives could be stated as a discussion of a decrease in the issues related to treatment or an enhancement of the patient's parameters.

Policy: The way in which the agent chooses its action in each of these states. It is a mapping that achieves the highest level of benefit in the long run among the states and actions.

Value Function: A function that is helpful in decision-making process to predict the potential gain an agent can accrue out of a particular scenario. A value function can be applied in the medical decision making to estimate impacts of different related treatment options on the long-run health [11].

CLASSIFICATION OF ALGORITHMS USED IN REINFORCEMENT LEARNING

Although there are many different approaches to RL, they can be roughly divided into two categories:

Model-Free Reinforcement Learning: In this method, the agent has a direct communication with the environment to assess the most propitious action to take without the modeling of the system [12]. This is very useful when the environment is complex and can hardly be modeled. Two primary categories of model-free RL techniques exist:

Value-Based Approaches: These approaches focus on estimating value of each activity in each state. It is here that the agent makes the choices of the best line of action based on these value appreciation. Establishing the expected value of an action performed in a given context is measured by Q-value in a widely discussed reinforcement learning technique called Q-learning [13].

Policy-Based Methods: These methods are learning policies directly rather than learning value functions. The probability distribution of actions is employed to educate the agent what to do in any given state. Policy Gradient that change policy to get better expected sum of reward is one of the technique [14].

Model-Based Reinforcement Learning: In model-based reinforcement learning the agent forms a model of the environment in order to predict the outcome of its action. One way the agent may be able to do this is by planning ahead by using a model of actions and their consequences; this makes sense especially where data is hard to come by. A model-based RL technique in health could capture many treatments and predict the health impacts of different interventions [15].

Reinforcement Learning: The exploration verses exploitation dilemma is one of the main challenges in reinforcement learning. Whereas exploitation is choosing the action with maximum known concentration based on exploitation, exploration involves the agent running various action to determine which one yields the best result. In RL, especially in medical applications, an optimal balance between exploration and exploitation is critical, and it was the case in RL, especially for the medical application. An agent may need to seek less explored treatment strategies for a given patient in cardiovascular therapy, for instance, but it has to also incorporate the information obtained from previous effective therapies in order to optimize the current line of treatment. This balance is very helpful in the healthcare industry since it ensures that the RL agent always follows the most well-known efficient approaches (exploitation) and yet the agent is flexible enough not to miss out on any other possible best treatment strategies (exploration). As for the constant and complex diseases, such as heart diseases in which a patient's condition can change very often, such dynamic change is particularly beneficial [16].

Healthcare Reinforcement Learning: Because reinforcement learning is designed for the cases with sequence decisions and choice making that involves uncertainty, it can be effectively applied to the healthcare domain. As a concept, RL can help serve cardiovascular therapy in optimizing several decisions at various moments, such as with medications, interventional timing, and patient's health characteristics measurement. Compared to other knowledge representation methods, RL is a very promising approach for achieving personalized medicine due to its ability to incorporate new knowledge and learn from it making the treatment regimens better with time. The end goal for using RL in cardiovascular therapy is to achieve better patients' outcomes through providing more accurate, malleable and personal treatment plans. Incorporation of a RL approach into cardiovascular treatment processes is possible due to distinct advantages of RL systems, encompassing the opportunity to improve therapeutic protocols in terms of combination, dosage and application methods not available before due to limitations of information processing capabilities, amount of medical data and real time interactions between a patient, or any other user of the healthcare system, and the RL system [17]. Through reinforcement learning, a robust and scalable structural solution to enhance the therapy regimes of cardiovascular diseases is made available. RL systems can adapt mid-intervention for improved patient health by using patient data feed backs to update the system. Nevertheless, problems of data quality, ethical questions, and clinical pragmatics must be solved to be able to implement RL in healthcare. Despite these challenges, there remains a reasonable likelihood that RL may alter individualized cardiovascular care, which offers a future path to develop and to apply to clinical reasoning [18].

APPLICATION OF REINFORCEMENT LEARNING IN CARDIO VASCULAR SYSTEM

Reinforcement learners can be used in a number of areas of cardiovascular medicine, such as the treatment of hypertension. The possibility that Reinforcement learning (RL) possesses to increased cardiovascular therapy procedure has benefitted from a lot of attention, bringing into focus a completely new dimension to personalized medicine. In detail, every patient's individual requirements could often be masked through conventional healing paradigms and the basic methodology entails the clinician's understanding and standard methodologies. RL is different from other methods due to its ability to learn and change over time while treating a patient because it interacts with the environment in its process. In cardiovascular care, RL can be applied to such areas as the development of individual approaches to treatment; regulation of dosages of prescribed medications; and patient supervision. Such applications could enhance the total therapy effectiveness, reduce the expenses and raise the overall performance of the process [19].

Customized Therapy Procedures: Most people have heard about reinforcement learning, which is used to make individual treatment plans probably among the most fascinating application of reinforcement learning in cardiovascular care. Therapies for cardiovascular diseases which include hypertension, heart failure, and arrhythmias are very special and often requires individual specification of the patient's physiological status. While there are general guidelines with respect to therapy, these proved to be too general, not taking into consideration the specifics of individual illness. For instance, the response that patients with heart failure have towards certain medications may depend on their age, their genetic make-up or prevalence of other medical conditions that may include diabetes. With RL, it is possible to build patient individualized treatment profiles flexible in time [20]. RL algorithms can adapt a list of which interventions are most appropriate to a specific subpopulation of a patient based on feedback from clinical outcomes. This might change the treatment to ensure that the therapy still aligns with state of the patient, if there is new information about the treatment. For instance, based on constant tracking of patients, an RL model may for instance look at the best drugs that can be administered or their recommended dosages to reduce hypertension or risk of heart attacks.

Flexible Drug Dosage Control: Medication management is an important aspect of therapy of cardiovascular diseases and RL has shown promise in achieving maximum medicine dose for a particular patient. Aminophylline, betablockers and statins and anticoagulants mostly need close dose adjustments to minimize side effects yet achieve their anticipated therapeutic goals. Traditional approaches to dosing are often based on manuals or norms universal for a certain population group, while attempting to ignore the variability of the patients' response to treatment or their metabolism rate [21]. That way, RL may perhaps furnish a more primeval technique of approaching the matter with medication dosage. RL algorithms can predict patient needs at the beginning of the cycle and, during treatment, consider the patient's history and current clinical characteristics (such as blood pressure, pulse, and biomarkers). In cases of anticoagulants such as warfarin for example, when the goal is to hold the patient in a therapeutic range that is absolutely free of bleeding complication, RL can be helpful in identifying the best dose regimen. This is because, through constant learning from the patient response to the experiments and continuously adjusting the dosage based on the continuous feedback received, the RL model gradually brings about better treatment results for the patient and minimizes the health complication side effects [22].

Improving the Timing of Treatment: When it comes to particular cardiovascular disease, timing surely does matter. The types of treatments like thrombolysis or percutaneous coronary interventions (PCI) that may be started at a particular time maybe fairly crucial throughout the restoration of patient survival; while other kinds of treatment maybe lifesaving measures in some cases like in acute myocardial infraction (heart attack) where early intervention can significantly improve the rates of patient survival. However, deciding the most appropriate time to conduct these treatments is complicated and varies from customer to customer. As RL facilities the optimization of cardiovascular therapy timing and takes into account the present state of the patient, concomitant illnesses, as well as the course of the disease, it can be used to determine the optimal time for initiating cardiovascular therapy. For instance, based on ECG, echocardiography, or biomarker data, RL algorithms can help to identify the right time to give a patient fibrinolytic therapy and other treatments [23]. In addition, through proper timing of giving the interventions to avoid adverse effects such as heart failure or stroke, RL will also assist patients with other chronic diseases to receive proper follow up care.

Systems for Real-Time Patient Monitoring: Especially for CHD patient's constant patient follow up has become an important complementary aspect of modern cardiovascular intervention. There are massive amounts of real-time data originating from such devices as wearable ECG monitors, smart watches, and implantable sensors on basic vital signs, including heart rate, blood pressure, and oxygen saturation. This information is used to assess the patient status and to make changes to patient management when they are required. However, the vast believes of data collected in any given period often inundate the clinicians, making it difficult for them to provide timely and accurate decisions. Through the RL mechanism, the real-time data can be monitored intelligently, recognize certain patterns of activity, provide alerts on important events, and even provide recommendations on the changes that should be made to the treatment regime. For instance, by repeatedly recording the data of heart rhythm and offering measures to avoid stroke or other outcomes, RL can help in the treatment of patients with atrial fibrillation (AF) [24]. Also, RL systems can detect relatively slight deviations from the norm of a patient, including heart rate or blood pressure, and recommend the necessary intervention, such as the change of medication or booking an appointment to see the doctor, before the situation worsens.

Enhancing Clinical Decision Support and Workflow: Again, RL has the potential of enhancing decision making regarding cardiovascular care beyond merely the care of one patient. It indicates that, RL systems can serve the purpose of a decision support system where they provide LSHC

BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

practitioner's real-time data to make better decisions. Indeed, it is extremely important when it comes to making high stakes decisions for critically ill patients such as in the ICU. Clinicians can have priority over the treatment strategies, organize the resource allocation and ensure that the right interventions are delivered on the right time using the RL algorithms that gives them options of action basing on the patient information and clinical guidelines. For instance, on the bases of patient's criticality and organization's capacity, RL could order the patients according to priority in relation to procedures like coronary angiography or PCI. Most of the applications of reinforcement learning may be implemented in cardiovascular medicine such as real-time patient monitoring, drug dosage control, individualized treatments and intervention timing. It is considered as an important instrument to improving patient status and creating individualized medicine due to the possibility of learning from the patient data and tuning the therapeutic decisions in real time [25]. As RL research progresses, the role that it plays in cardiovascular care could totally revolutionize diseases' treatment by enhancing the characteristics of treatments and making them patient-specific.

AI AIDED CARDIOVASCULAR DISEASES DIAGNOSIS



Figure: 1 showing AI aided cardiovascular diseases diagnosis

BULLETIN OF INFORMATICS
BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

ORGANIZATIONS ACHIEVEMENTS: SUCCESS STORIES AND CASE STUDIES

Despite the fact that there are few success and case studies related to the use of reinforcement learning in cardiovascular therapy, these two parts demonstrate how RL can improve long-term performances, personalize further treatment, and increase the level of patient care. The above illustrations demonstrate SM as a practical tool for handling such real-life HL issues as dynamic treatment planning, the real-time monitoring, and MD management. Studying these cases, it is possible to notice more about the ways RL approaches are applied in cardiovascular activity and the pragmatic benefits they offer to such cardiovascular patients as well as physicians [26].

RL for Customizing Warfarin Management and Anticoagulant Therapy: The personalised dosing of anticoagulants, particularly warfarin, is possibly the most acknowledged use of RL in cardiovascular medicine. People with AF, DVT, or who have undergone heart valve replacement surgery mostly use warfarin to prevent formation of blood clots. However, unlike most drugs, warfarin has a very narrow therapeutic range, so dosage should be closely monitored to reduce the risk of thrombosis or bleeding. There’s also warfarin, which counteracts blood clotting by bringing the International Normalized Ratio (INR) test, tracking blood clotting time, to the right level that requires periodic blood tests to monitor. Traditional techniques of regulating warfarin dose involve a standard therapeutic range or doctor-initiated and based on the achievement of INR result [27]. These approaches may not factor in the dramatic differences that may exist with the kind of response that patients exhibit to the medication hence unsatisfactory outcomes may be expected. Due to this, the therapy has been in the recent past adjusted using RL based on patient data from INR levels, age, weight; food and genetic factors affecting warfarin metabolism.

The interaction of researchers at the University of California that developed an RL algorithm capable of individualised dosage of warfarin is one of the applications of RL that has been achieved. Through the altered pattern of response to INR from the patients, the algorithm improved the regularity of INR and lessened the instances of thrombosis and hemorrhage. A primary value of the RL-based strategy was that is was more effective than traditional dosing methods in maintaining INR levels within the therapeutic range to enhance patient stability. This illustration shows how RL can handle complex decisions and decisions that change over time particularly when patient oriented care is desirable [28].

Improving the Control of Blood Pressure: Another important application of RL has been noted in improving the blood pressure regulation in particular for patients with hypertension or risk factor for stroke. Hypertension is one of the biggest risk factors for cardiovascular diseases, and how to target blood pressure is a significant goal in reducing the risk of acute myocardial infarction, stroke, and renal failure. However, control of hypertension would require decisions about the class of antihypertensive to use, the dose to administer, the time of drug administration, and would often demand instabilities to be made based on the clinical status of the patient on a regular basis. A medical case study was conducted by a team at Stanford University to design a personalised blood pressure control using reinforcement learning (RL). The RL algorithm used information regarding the patient’s blood pressure, types of medicines previously administered and the patient’s age and gender in order to select the right drug and the suitable dosages for each patient. Different treatment regimens of the system and the acquisition and utilization of feedback, which allows doctors to provide an individual and effective scheme for controlling high blood pressure [29]. The results of the study were positive because RL algorithm for controlling hypertension hurt more than conventional approaches.

RL for the Management of Heart Failure: Similarly, when it comes to the use of RL as a means to improve patient outcome there has been success in another condition – heart failure (HF). Most heart failure patients require complex treatment care strategies that can include prescription medicines, alterations in diet and perhaps even operations. That is, to improve cardiac function with ACE inhibitors or beta-blockers, control patient fluid levels with diuretics and apply the requirements

BULLETIN OF INFORMATICS
BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

for heart failure treatment to implement exercise and diet. One of the success stories in managing heart failure through the use of RL is in the timing and dosage of heart failure drugs. Patients' physiological metrics, such as heart rate, blood pressure, recent weight changes, and laboratories (e.g., BNP) have been used together with RL algorithms to predict which treatments and doses would be helpful. Another study on RL acted on patients of heart failure performed in the University of Toronto where the authors used an RL-based technique of treatment. Through the dynamic and continual adjustment in patients' dosage as per updates given by the patient's constant feedback from the monitoring devices such as wearable heart monitors and remote patient monitoring equipment, the algorithm succeeded in the optimal drug dosage [30].

Cardiovascular Event Prediction and Prevention: To prevent cardiovascular events, such as heart attacks, strokes, and arrhythmias, from occurring in the first place, reinforcement learning is also applied to prediction of such events. Clinicians may perhaps prevent people from dying and reduce the instances when they have to perform an emergency action when such cases are expected beforehand. MIT research team recently used RL to estimate the likelihood of a cardiovascular event in high-risk population such as diabetic, hypertensive or genetically predisposed patients and healthy individuals. The RL model was trained using a large number of patient data records containing demographics, medical histories, life style, and test reports [31]. From actual data collected following patient monitoring, RL was employed to develop a model that would dynamically predict the probability that a particular patient would suffer a cardiovascular event within a particular time horizon.

Comparing these results with other more traditional risk assessment models, such as the Framingham Risk Score, the model derived from our analysis outperformed the others. Moreover, the RL based system could even keep updating the results with new data that were entering in and providing more accurate and timely treatment. Using the institute success, this study shows that RL is a valuable tool in the war against heart diseases as it prevents CVD and enhances treatment. Reading these success stories and cases which are examples of the application of reinforcement learning, one cannot but see how this approach will transform cardiovascular management. RL has been shown to improve patient outcomes and advance the science of personalized medicine, whether as an adjunct to a risky disease such as heart failure or to optimize patients' blood pressure or their anticoagulation therapy [32]. As real-time data are fed into the RL algorithms, and the algorithms are integrated into clinical practices, the potential to learn from the data and adapt treatment plans will ultimately become increasingly significant in refining cardiovascular therapy. However, more study and validation are needed to ensure that these technologies can be implemented safely and reliably on a broader level.

IMPLEMENTING REINFORCEMENT LEARNING IN CARDIOVASCULAR THERAPY: OBSTACLES AND RESTRICTIONS

The application of RL in cardiovascular therapy possesses high potential in terms of the care quality improvement and desired treatment individualization; yet, there are some challenges and limitations to it. Potential prospects of RL in modern cardiological practice are still beyond the considerable number of technical, ethical, clinical, and regulatory questions that arise before RL is utilized in routine practice of CVT. Challenges in RL application to cardiovascular medicine will also be highlighted in this part, such as issues concerning data, algorithmic complexity, safety concerns, interpretability, and regulatory approval [33].

Availability and Quality of Data: Lack of big and accurate datasets that would enable training of the algorithms in cardiovascular medicine is one of the biggest challenges of applying RL. The building blocks of RL algorithms are feedback loops acquired through an agent's interaction with environment in real time. This can only work if the following parameters are implemented, and at their optimal; Complete data, accurate data, and up-to-date patient data [34]. However, there are a number of data-related issues facing the healthcare sector:

BULLETIN OF INFORMATICS
BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

Data Fragmentation: Generally, information on healthcare often exists across multiple sites, organisations, and systems to a significant extent. Obtaining the data needed for training RL models may prove difficult because electronic health records (EHRs) are not entirely standardized and patient records may be fragmentary or scattered across different sources [35].

Missing Data: In database, there is always a probability of having some data missing, and this aspect is quite common in the healthcare databases. Incomplete or missing patient information may strongly interfere with the learning process of RL algorithms. For instance, the model might seriate out prescriptions that require an accurate account of a patient's clinical history, test result, or conformity to medication.

Data security and privacy: Cardiovascular data is highly sensitive especially if combined with other pieces of personal information. The subject is further complicated by need to ensure the patients' confidentiality and obey strict regulations like the HIPAA in the United States [36]. Pristine concerns, which are unauthorized access and data breaches threaten patient safety and the educational process.

DIFFICULTY AND EXTENSION OF METHODS

They are inherently difficult due to the need for long-term training for a number of interactions, construction of reward function and tuning of hyper parameters. RL's intricacy creates a number of challenges:

Long Training Times: Namely, it often requires much time and computing resources to train RL algorithms especially in healthcare organizations. It could take months or even years of patient interaction data to update a model in RL when patients' dynamics shifts in cardiovascular medicine, which hampers the practical implementation of the model in the clinical practice [37].

Over fitting and Generalization: Some RL algorithms when trained on some data sets might have had a hard time applying on different population or new patients. Various and diverse aspects may play a role in cardiovascular disorders including; age, gender, genetics, comorbid illnesses, and lifestyle. In larger patient population samples or when patients arrive with different or unique diseases, an RL model trained on a similar dataset can do poorly [38].

Reward Function Design: This is why the job of creating an appropriate reward function plays a crucial part in the RL learning process. In this paper, clinical objectives such as improvement of patient outcome, reduction of risk of harm, and reduction in hospitalizations should be appropriately incorporated in the incentive function within the healthcare industry [39]. That is why it is rather challenging to define such a function as it is necessary to include the results of complex medical conditions which are often qualitative and may vary in the course of time.

Safety and Ethical Issues: Some of the ethical concerns in applying RL in cardiovascular medicine include concerns to do with algorithmic decisions making and patient safety.

Accountability: The issue of identification of accountability arises as a rather challenging one as RL systems are used more actively to recommend treatments. A particular problem arises in deciding whether an adverse event that occurs as a consequence of some RL-driven decision, originated from the algorithm, the data, or the physicians' adherence to the recommendations [40]. This raises questions about the extent to which the practitioner trusts the given algorithm, and who is responsible for patients' safety.

Fairness and Bias: As any other machine learning systems, RL algorithms are not immune to bias in the training data set. Recommendations that benefit some groups and harm others, e.g. minorities or patients with rare diseases may also be provided if the RL model was trained on a dataset that does not include people from a variety of backgrounds. Thus, decisions should be made fairly to prevent aggravating already-existing differences in a population's health status [41].

Informed Consent: Issues concerning patient's self-determination and decision-making are raised through the application of RL systems in treatment settings. Some of the patients might not want to participate in therapies guided by JL&BT models since they lack a complete understanding of how the RL-based recommendations are developed. To maintain public confidence in the continuity of a healthcare delivery system and to ensure that the patient acceptance of the new technologies such as AI is enhanced, it becomes important that patients are informed on how AI will be integrated into their care delivery plans [42].

Transparency and Interpretability: One of the critical challenges in the adoption of RL systems in the healthcare sector is the 'black box' nature of many of the models that underpin RL, including those employing ML. However, for the findings from RL algorithms to be applied in clinical settings, clinicians need to understand and have faith in the recommendations made.

Lack of Transparency: Many RL algorithms, especially the emerging DRL models, still remain partly opaque and their inner mechanisms, especially decision-making processes are not evidently comprehensible [43]. To some extent, this lack of openness might undermine systemic trust, as clinicians will find it hard to reason through the logic behind the model guidelines.

Clinical Decision Support: For RL to be truly useful in clinical practice it must act simply as an aid to the clinicians to help them make more informed decisions, not as a replacement for the clinicians. For this to happen, clinicians require understanding of how and why the RL algorithm arrived at a specific recommendation. AI Need to be Explainable to Incorporate RL models into healthcare procedures, work must be done to achieve explain ability [44].

Legal and Regulatory Obstacles: As has been noticed, there are legal and regulatory barriers to incorporating RL in cardiovascular therapy. Regulatory organizations, including the USA The FDA has laid down the following stringent measures for clearance of algorithms and medical devices [45]. However, they have not refined clear, comprehensive working standards interpreting the role of RL as an integral part of clinical decision-making processes.

Liability: Again legal issues of therm as to the question of who is a liable arise in the instance an RL-based therapy provokes negative occurrences or has no desired impacts. In reality, is the healthcare provider, the RL system manufacturer, or both responsible for patient harm? RL usage in the clinical practice, however, is limited by such legal uncertainties [46].

There are over 30 significant challenges that need to be overcome in order to use reinforcement learning to revolutionise cardiovascular therapy. There is much in the way of effort, collaboration, and innovation that exists to address these hurdles, which include issues related to data integrity and sorting algorithms, ethical questions and legal barriers still to be figured out at the time of writing. Several hurdles need to be cleared in order to take the RL to its full potential in improving patient outcome [47]. It is however expected that with a growth of the field most of these challenges will be addressed and hence create a way for RL to be applied in cardiovascular medicine.

POSSIBLE FUTURE ROADS/REPERCUSSIONS OF REINFORCEMENT LEARNING IN CARDIOVASCULAR MANAGEMENT

In the AI for health care, RL is an emerging area especially in cardiovascular therapy optimization. With further advancements in RL algorithms:", RL is poised to transform the entire process of cardiovascular treatment and offer new opportunities to enhance patient safety, accuracy and individualization of treatment. In this section, the future of RL in cardiovascular therapy will be outlined along with possible technological advancements, integration of RL with other AI techniques, the potential of real-time, dynamic treatment and the global implications of such treatments on the patient and healthcare organization [48].

Developments in Algorithms for Reinforcement Learning: The enhancement of algorithms itself is certainly one of the most important research directions in RL for cardiovascular therapy. Due to the current stages of RL models in machine learning, future advancements will enhance, improve and provide the models with the capability to solve even more complex decision making problems.

Better Exploration and Exploitation: RL algorithms allow a trade-off between exploitation, which means choosing the most easily recognizable actions, and exploration which means taking other actions. This balance is critical in healthcare as to be effective the RL system has to adapt to patient circumstances but at the same time be certain that the rational approach in administering therapies is achieved [49]. Improvements in exploration strategies are expected to be integrated into subsequent RL models to ensure that when the traditional treatments are ineffective, some alternative therapy options are considered.

Meta-Learning: Otherwise, known as learning to learn, meta-learning is a subset of machine learning that deals with designing models that can adapt to new tasks at a fast rate while using minimal data. Meta-learning could potentially enable generalisation of the RL systems across the patient's demographic attributes or in specific medical scenarios surrounding cardiac therapy. This would increase its practicality in real clinical environment and allow one to address the needs of the certain patient faster. Other fields have already demonstrated the possibility of the use of Deep Reinforcement Learning (DRL), which is a joining of deep learning and reinforcement learning. DRL is capable of converting large and complex data types like sensor data or medical imaging which is applied in cardiovascular care [50]. Improved DRL algorithms that are capable of learning from diverse input, such as laboratory results, patient histories and ECG, as well as improving decisions in complex situations could be provided in further research.

Natural Language Processing (NLP): The large volume of patient information is maintained in several unstructured modes such as clinical notes, published material regarding various medical conditions, and discussion with the patients. The unstructured data which can be extracted from such sources can then be used to gain cheap insights by NLP which can then be fed to RL algorithms. When integrated with NLP, RL systems are capable of accumulation of the whole context of a patient's health, providing clinicians with a constantly enriched flow of data that contributes to developing suggestions concerning further therapies [51].

Computer Vision: Imaging is a critical component of the care delivered to patients in cardiology. To this end, RL integrated with computer vision models analyzing medical pictures like CT or echocardiograms would allow RL systems to make judgments regarding numerical data, and image features across tissue, organs, and other cardiomyopathy aspects. This would make it possible to change treatment regimens in response to visual signs of the patient's status in real time and with more of an element of precision than is currently possible [52].

Continuous Monitoring and Adjustment: RL systems could continuously monitor other aspects of a patient such as blood pressure, pulse rate, and oxygen levels with wearables and remote patient monitoring set to become common. This data could be utilized within the RL algorithms to change treatment plans in real time, inciting changes to the medication administration schedule or other treatment plans or options, such as rescheduling anti-hypertensive medication or encouraging the patient to exercise or stop smoking. Presumably, through prevention of such problems or exacerbations, this degree of flexibility might provide the potential to substantially improve patient outcomes in the short term [53].

Personalized Medication Dosing: First and foremost, one of the biggest challenges that cardiovascular medicine has is ensuring that patients receive the right dose of medication. For those drugs that have narrow therapeutic ranges such as anticoagulants, warfarin in particular, this is particularly important. Using real-time data, RL systems may adjust such drugs' dosing as needed to maintain their patients within the therapeutic window and decrease the risk of adverse effects and suboptimal care.

BULLETIN OF INFORMATICS
BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

IMPACT ON PRACTICE AND HEALTH CARE COSTS

If incorporated more into cardiovascular therapy, application of RL systems can expand the capability of operation of healthcare systems. When implemented effectively, minimizing unnecessary processes, mitigating risk incidents, and redesigning client interfaces all may reduce healthcare costs over time as RL enhances the treatment planning capacity of the CIS [54].

Optimizing Resource Allocation: With the help of RL, it also becomes easier to optimise the application of healthcare resources, be they medical equipment, human resources in the form of staff, OR time and hospital bed space. By enabling the prediction of patient outcomes as well as the precise estimate of need for all potential treatments, RL systems can assist healthcare administrators in identifying patients with the greatest need, minimizing waiting time, and ensuring that efforts and money are being invested where they will be most helpful [55].

Cost-Effective Precision Medicine: RL can prevent unnecessary costs related to side effects and the use of ineffective interventions, as well as can optimize the dose and frequency of treatments, providing extensive individualized approaches instead of the trial-and-error concept of medication. Costs appear to be brought down over all treatment because few adverse responses mean that the patient undergoes few follow up sessions or readmissions. In addition, because alternatives can be less invasive but equally efficacious, RL's capability of identifying superior treatment trajectories might help physicians avoid costly and aggressive treatments [56].

Enhanced Quality of Life: Consequently, thus, for the patients, RL is able to increase quality of life on an overall picture further to survival. RL may therefore make a patient feel better, not go to hospital more often, and have greater freedom and self-fulfilment as fewer side effects will occur, adverse events will be prevented, and more personal attention will be given. There is a very high prognosis for reinforcement learning in cardiovascular medicine. Because of new approach in the algorithm construction, using several AI techniques simultaneously, and availability of real-time adaptive control approach, RL has the promising future for complete redesign of cardiovascular disorders' management. By enhancing patients' outcomes, promoting appropriate use of available resources, and enhancing treatment personalization, the role of RL in enhancing the efficacy, cost, and availability of cardiovascular interventions is well-documented [57]. However, challenges like data quality, computational expensive and regulatory permission need to be solved before true ability of RL can be achieved. While trying to solve these issues, RL may well become an essential element in cardiovascular practice, which will alter how physicians interact with patient care and treatment and even diagnostic processes.

A SHORTCOMING WHEN UTILIZING REINFORCEMENT LEARNING IN CARDIOVASCULAR THERAPY

As a result of a patient-specific reparative therapy and, therefore, real-time decision making, RL methods in cardiovascular treatment can drastically enhance the quality of the assistance. To ensure that patient's safety, autonomy, and equity are preserved it said that there are several ethical concerns that arises from the use of RL, as with the case with any new technology in healthcare. Some of the ethical issues that mean well for AI empowering clinical decision-making include the following; patient privacy and consent, openness, and responsibility of the AI engine. This section discusses the primary ethical issues that pertain to cardiovascular therapy with the use of RL and their specific recommendations [58].

Autonomy and Informed Consent for Patients: The basic ethical principle of patient information assurance with regard to the treatments and their risk factors, as well as potential benefits that can be obtained in the course of the treatments, is an important aspect of informed consent. Patients should know how these AI models can influence their care since more RL systems are used to decide on treatment plans [59].

BULLETIN OF INFORMATICS
BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

Autonomy and Control: Another important ethic involved in RL is whether patients would be in fully charge of their treatment decisions. In traditional health care delivery settings, patients and health care providers, often engage in shared decision making. However, as the decisions of treatments can mainly be decided by the algorithms, users may possibly lose their decision making power when using the RL systems. For patients' independence and trust in the healthcare system maintenance, patients should have an opportunity to talk about AI-based suggestions and to participate in decision-making [60].

Educating Patients: The concerns patients have in this regard must be addressed and medical practitioners and organizations must let patients know their role of RL in their treatment. In order to ensure patients' capacity to make an informed choice, the following principles are thought to be valuable: The public needs to know how decisions are made by RL systems, and how these systems extend rather than supplant existing professional knowledge [61].

Security and Privacy of Data: Protection of the patient data is always important when the data is being processed similar to the case with most of the AI applications such as the RL model that requires massive amounts of health information that is private [62]. Confidentiality that relates to treating cardiovascular patients involving genetic information, medical history, and current medical condition may be compromised [63].

Data Breach: A notable fact is that for better RL systems, massive datasets with high quality are a necessity. However, this also means that these systems store, access and process personal health information. Patient's identifiable data may be compromised during instances of data breach in case these data archives are not properly protected. Some such risks may lead to the loss of trust in the AI-powered solutions and, therefore, inconvenience the patients, put their identity at risk of theft, cause discriminated against, or stigmatized [64].

Data Ownership: Ownership of patient information is a major ethical issue. As to who owns the data collected for RL systems in many healthcare contexts – the patient, the healthcare provider or a third party, operating the system, is not always clear. To ensure the rights of the patient as well as the ethical use of data about patients certain polices and agreement concerning data ownership, data use and data consent should be developed [65].

Privacy Issues: Monitoring of the patient's health status can be continuous if wearables and other technologies of real-time data tracking are installed. This raises privacy problems though RL systems can be endowed with valuable information to better treatment. The monitoring and analysis of all their health relevant features by algorithms without the patients' direct control may cause discomfort to patients [66]. A never-ending ethical question in this practice will be between the need to gain benefits from surveillance and continuous monitoring comparative to the need to respect people's privacy.

ALGORITHMIC FAIRNESS AND BIAS

This being said, we can list the following two values as the key ethical considerations when applying RL in healthcare applications: fairness, as well as avoiding the endowment effect arising from the algorithm. RL algorithms can be biased and act in the same way as any other machine learning system influenced by the data they work with. Decisions that are especially detrimental for specific patient populations – such as minorities or patients with rare diseases – may be made if the dataset that YouTube RL models was trained on included far fewer such patients than in the general population [67].

Healthcare Disparities: However, the manifestation of cardiovascular diseases in general depends on some factors, such as genetics and life experience, as well as the ability to pay for the necessary medicines and services and belonging to different socioeconomic backgrounds. An RL system can be either less useful or even rather harmful to other populations thereby contributing to the health inequalities if an RL model had been trained on the dataset containing predominantly white males for instance [68].

Reducing Bias: To ensure equal output, the RL model has to be trained on a diverse data set that contains patients' information of all age, gender, race, and income levels. Additionally, to capture the potential of new data that may contain biases that may arise and present themselves at different times, continuous monitoring is needed. HEALTHCARE PROFESSIONALS: approaches to minimize bias and facilitate equality of RL-driven therapy recommendations are the evaluation and optimization of algorithms [69].

Providing Equal Access: It is also important to understand that not all healthcare systems are kind of equal when it comes to the implementation of some of the newest AI technologies like RL. Some citizens from the rural or low-resources area may not have access to the devices or any infrastructure on which to receive the RL-enhanced care. The fact is that the application of these technologies cannot deepen existing health disparities – it is therefore crucial to ensure that accessibility of such technologies is non-discriminatory [70].

RESPONSIBILITY AND LIABILITY

When RL systems are beginning to be used more often in making decisions specifically related to the healthcare field then accountability and responsibility concerns tend to become more complex. Sometimes it can be difficult to point a finger when an RL algorithm gives a recommendation of a treatment process that is actually wrong and has negative consequences on the patient.

Shared Responsibility: In standard medicine, doctors being professionals, bear the full responsibility for the decisions and actions they make. Finally, when an RL system is applied, it is not clear whether the error belongs to the healthcare providers who interfaced the RL system or the algorithm developers or both [71]. Decision making then becomes mired in confusion and hence the issue of accountability gets blurred especially when the AI's decision is not entirely unambiguous or easily decipherable.

Legal and Regulatory Frameworks: Thus, based on these challenges, the requirements of developers, doctors, and other parties relevant to the application of RL in cardiovascular treatment must be outlined by the frameworks. To guarantee the safety of patients and to hold the key stakeholders responsible, the correct guidelines should be defined [72].

Explain ability and Transparency: A significant ethical concern in relation to RL application in healthcare is the closed and not explain able nature of the decision-making process. This results in many an RL algorithm being categorized by people as 'black boxes' whereby people find themselves hard to decipher why an algorithm had to make a particular decision. The major problem that practitioners can experience when utilizing such systems is that they often do not disclose the details of their work [73].

Clinical Decision Support: RL systems are not designed to replace clinicians in cardiovascular care; instead, they are designed to provide clinicians with better Judgment. Clinicians have to understand why X is suggested though, if they are to buy into these systems. Thus, attempts should be made to design AI-based models that would describe the process and the reasons for suggesting certain treatments [74].

Patient Trust: This means that patients have to trust that the RL systems making these choices, are doing so, for the benefit of the patient. To build this trust, there is need to explain ability. It would appear that using AI would only benefit patients where they can follow the rationale for the recommended treatments and/or agree to any AI being applied to their case. As with many trends in the application of RL in cardiovascular medicine, these advances have to be considered and balanced on a number of ethical issues. To ensure that RL systems are applied in clinical practice ethically the following questions of ethical concern need to be answered: Informed consent, data protection, fairness, responsibility and openness [75]. As RL technology evolves there will be the need to balance the legal implication that comes with use of the tools hence ethicist, legal experts, healthcare practitioners, and legislators will have to engage in constant discussion. Ultimately, we stipulate that these measures will enhance confidence in RL-driven treatments for benefiting all patients, ultimately raising the bar for cardiovascular treatment.

CONCLUSION

One can mention all the trends for revolutionizing cardiovascular care and apply RL in cardiovascular therapy optimization. Reviewing the existing literature on RL, we revealed the current state of the technique in this field, possible applications, challenges, and potential impacts on ethical norms in this text. Some of the RL specialties include customized management care, finding the right dose of medicine, and making decisions where a patient's condition is dynamically changing. Using elements such as computer vision, NLPs, and prediction, RL systems are the potential tools for boosting the accuracy and efficiency of cardiovascular therapy.

However, RL in midst of its potential in healthcare contexts, is not an easy task free from challenges. Data of high quality and variety, algorithmic surveillance, and updating to curb biases while using RL and the seamless fit of AI models in current healthcare practice are crucial for RL systems' efficacy within healthcare. Thus, safety and effectiveness can only be achieved if RL models are clinically tested, explainable AI is created, and there must be some strict testing and regulation. Precisely, what should be done is to address the ethical considerations in RL of cardiovascular therapy. Obtaining patient's trust and ensuring provision of just and equitable treatment entails the following; addressing problems to do with informed consent, patient's autonomy, personal data protection and use of algorithms, fairness, responsibility and self-reporting. The following are some of the ethical issues that occasion the use of this technology, and, in order to obtain the maximum benefits from AI technology, as well as to maintain the recognized integrity of the health systems, the indicated problems must be solved.

That is why there are a lot of fascinating possibilities for RL in cardiovascular therapy in the close future. It is expected that further advancement in AI and machine learning methods will improve the accuracy as well as the application breadth of RL systems. Due to the possibilities of offering unique treatment strategies that are successively adapted to match the requirements of a certain patient, these technologies can be called the means for the radical shift in the approach towards cardiovascular diseases. Moreover, based on RL, real time interventions and prevention of cardiovascular issues can be achieved through creative and advance technological base such as wearable health devices and remote monitoring technologies. It will in the long run lead to better patient status and reduced costs of healthcare. Address the considerations of ethical, sociological, and technical if ever the great potential of RL in healthcare is to be realized and this is where all healthcare professionals, researchers, regulators, and ethicists are required to join in. For that reason, when those problems are addressed, the reinforcement learning will bring real change to cardiovascular therapy, getting us one-step closer to an ideal future where the healthcare is tailor made, efficient and accessible for all.

REFERENCES

1. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. Jama. 2014; 312(1):90–92. https://doi.org/10.1001/jama.2014.5804 PMID: 24838355
2. Rhee C, Dantes R, Epstein L, Murphy DJ, Seymour CW, Iwashyna TJ, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. Jama. 2017; 318(13):1241–1249. https://doi.org/10.1001/jama.2017.13836 PMID: 28903154
3. Paoli CJ, Reynolds MA, Sinha M, Gitlin M, Crouser E. Epidemiology and Costs of Sepsis in the United States-An Analysis Based on Timing of Diagnosis and Severity Level*. Critical Care Medicine. 2018; 46 (12):1889–1897. https://doi.org/10.1097/CCM.0000000000003342 PMID: 30048332

4. Marik P. The demise of early goal-directed therapy for severe sepsis and septic shock. Acta Anaesthesiologica Scandinavica. 2015; 59(5):561–567. https://doi.org/10.1111/aas.12479 PMID: 25656742
5. R. Pirracchio, M. L. Petersen, M. Carone, M. R. Rigon, S. Chevret, and M. J. v. d. Laan, "Mortality prediction in intensive care units with the super ICU learner algorithm (SICULA): A population-based study," Lancet Respir. Med., vol. 3, pp. 42–52, Jan. 2015.
6. Arif, A., Khan, A., & Khan, M. I. (2024). Role of AI in Predicting and Mitigating Threats: A Comprehensive Review. *JURIHUM: Jurnal Inovasi dan Humaniora*, *2*(3), 297-311.
7. L. A. Celi, R. G. Mark, D. J. Stone, and R. A. Montgomery, ""Big Data" in the intensive care unit. Closing the data loop," Amer. J. Respir. Crit. Care Med., vol. 187, pp. 1157–1160, Jun. 2013.
8. B. Gholami, W. M. Haddad, and J. M. Bailey, "AI in the ICU: In the intensive care unit, artificial intelligence can keep watch," IEEE Spectr., vol. 55, no. 10, pp. 31–35, Oct. 2018.
9. D. Shillan, J. A. C. Sterne, A. Champneys, and B. Gibbison, "Use of machine learning to analyse routinely collected intensive care unit data: A systematic review," Crit. Care, vol. 23, pp. 1–11, Aug. 2019.
10. Khan, M. I., Arif, A., & Khan, A. R. A. (2024). AI-Driven Threat Detection: A Brief Overview of AI Techniques in Cybersecurity. *BIN: Bulletin Of Informatics*, *2*(2), 248-261.
11. J. C. Y. Seah, J. S. N. Tang, A. Kitchen, F. Gaillard, and A. F. Dixon, "Chest radiographs in congestive heart failure: Visualizing neural network learning," Radiology, vol. 290, pp. 514–522, Feb. 2019.
12. L. Li et al., "Using artificial intelligence to detect COVID-19 and community-acquired pneumonia based on pulmonary CT: Evaluation of the diagnostic accuracy," Radiology, vol. 296, pp. E65–E71, Aug. 2020
13. L. Chen, O. Ogundele, G. Clermont, M. Hravnak, M. R. Pinsky, and A. W. Dubrawski, "Dynamic and personalized risk forecast in step-down units. Implications for monitoring paradigms,"Ann. Amer. Thoracic Soc., vol. 14, pp. 384–391, Mar. 2017.
14. S. Nemati, A. Holder, F. Razmi, M. D. Stanley, G. D. Clifford, and T. G. Buchman, "An interpretable machine learning model for accurate prediction of sepsis in the ICU," Crit. Care Med., vol. 46, pp. 547–553, Apr. 2018.
15. C. W. Seymour et al., "Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis," JAMA, vol. 321, pp. 2003–2017, 2019.
16. C. S. Calfee et al., "Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: Secondary analysis of a randomised controlled trial," Lancet Respir. Med., vol. 6, pp. 691–698, Sep. 2018.
17. S. Liu, K. C. See, K. Y. Ngiam, L. A. Celi, X. Sun, andM. Feng, "Reinforcement learning for clinical decision support in critical care: Comprehensive review," J. Med. Internet Res., vol. 22, Jul. 2020, Art. no. e18477.
18. W.-H. Weng, M. GAO, Z. He, S. Yan, and P. Szolovits, "Representation and reinforcement learning for personalized glycemic control in septic patients," 2017. [Online]. Available: http://arxiv.org/abs/1712.00654
19. N. Prasad, L. Cheng, C. Chivers, M. Draugelis, and B. E. Engelhardt, "A reinforcement learning approach to weaning of mechanical ventilation in intensive care units," 2017, arXiv:1704.06300.
20. D. Lopez-Martinez, P. Eschenfeldt, S. Ostvar, M. Ingram, C. Hur, and R. Picard, "Deep reinforcement learning for optimal critical care pain management with morphine using dueling double-deep Q networks," in Proc. Annu. Int. Conf. IEEE Eng. Med. Biol. Soc., 2019, pp. 3960–3963.
21. A. Raghu, M. Komorowski, L. A. Celi, P. Szolovits, and M. Ghassemi, "Continuous state-space models for optimal sepsis treatment: A deep reinforcement learning approach," in Proc. 2nd Mach. Learn. Healthcare Conf., 2017, pp. 147–163.
22. M. Komorowski, L. A. Celi, O. Badawi, A. C. Gordon, and A. A. Faisal, "The artificial intelligence clinician learns optimal treatment strategies for sepsis in intensive care," Nature Med., vol. 24, pp. 1716–1720, Oct. 2018.

23. B. K. Petersen et al., “Deep reinforcement learning and simulation as a path toward precision medicine,” J. Comput. Biol., vol. 26, pp. 597–604, Jun. 2019. [20] S. Dugani, J. Veillard, and N. Kissoon, “Reducing the global burden of sepsis,” Can. Med. Assoc. J., vol. 189, pp. E2–E3, Jan. 2017.
24. C. M. Torio and B. J. Moore, “National inpatient hospital costs: The most expensive conditions by payer, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet], Rockville MD, USA: Agency for Healthcare Research and Quality (US), Feb. 2006. [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK368492/
25. J. E. Gotts and M. A. Matthay, “Sepsis: Pathophysiology and clinical management,” BMJ, vol. 353, May 2016, Art. No. i 1585.
26. M. M. Levy, L. E. Evans, and A. Rhodes, “The surviving sepsis campaign bundle: 2018 update,” Intensive Care Med., vol. 44, pp. 925–928, Apr. 2018.
27. M. Radovanovic, A. Nanopoulos, and M. Ivanovic, “Hubs in space: Popular nearest neighbors in high-dimensional data,” J. Mach. Learn. Res., vol. 11, no. 86, pp. 2487–2531, 2010.
28. A. E. Johnson et al., “MIMIC-III, a freely accessible critical care database,” Scientif Data, vol. 3, May 2016, Art. No. 160035.
29. R. P. Dellinger et al., “Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock,” Intensive Care Med., vol. 39, pp. 165–228, Jan. 2013. DRUDI et al.: REINFORCEMENT LEARNING MODEL FOR OPTIMAL TREATMENT STRATEGIES IN INTENSIVE CARE 815
30. Khan, M. I., Arif, A., & Khan, A. (2024). AI's Revolutionary Role in Cyber Defense and Social Engineering. *International Journal of Multidisciplinary Sciences and Arts*, *3*(4), 57-66.
31. E. P. Raith et al., “Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit,” JAMA, vol. 317, Jan. 2017, Art. no. 290.
32. AF. S. V. d. Oliveira et al., “Positive fluid balance as a prognostic factor for mortality and acute kidney injury in severe sepsis and septic shock,” J. Crit. Care, vol. 30, pp. 97–101, Feb. 2015.
33. J. Waechter et al., “Interaction between fluids and vasoactive agents on mortality in septic shock,” Crit. Care Med., vol. 42, pp. 2158–2168, Oct. 2014
34. Davenport EE, Burnham KL, Radhakrishnan J, et al: Genomic landscape of the individual host response and outcomes in sepsis: A prospective cohort study. Lancet Respir Med 2016; 4:259–271
35. Arif, A., Khan, M. I., & Khan, A. (2024). An overview of cyber threats generated by AI. *International Journal of Multidisciplinary Sciences and Arts*, *3*(4), 67-76.
36. Orde S, Slama M, Yastrebov K, et al; College of Intensive Care Medicine of Australia and New Zealand [CICM] Ultrasound Special Interest Group [USIG]: Subjective right ventricle assessment by echo qualified intensive care specialists: Assessing agreement with objective measures. Crit Care 2019; 23:70
37. Shimabukuro DW, Barton CW, Feldman MD, et al: Effect of a machine learning-based severe sepsis prediction algorithm on patient survival and hospital length of stay: A randomised clinical trial. BMJ Open Respir Res 2017; 4:e000234
38. Adams R, Henry KE, Sridharan A, et al: Prospective, multi-site study of patient outcomes after implementation of the TREWS machine learning-based early warning system for sepsis. Nat Med 2022; 28:1455–1460
39. Boussina A, Shashikumar SP, Malhotra A, et al: Impact of a deep learning sepsis prediction model on quality of care and survival. NPJ Digit Med 2024; 7:14
40. Catling FJR, Nagendran M, Festor P, et al: Data-driven decision support for individualised cardiovascular resuscitation in sepsis: A scoping review and primer for clinicians. medRxiv 2023.08.26.23294666
41. Lin P-C, Huang H-C, Komorowski M, et al: A machine learning approach for predicting urine output after fluid administration. Comput Methods Programs Biomed 2019; 177:155–159

42. Tang Y, Brown S, Sorensen J, et al: Reduced rank least squares for real-time short term estimation of mean arterial blood pressure in septic patients receiving norepinephrine. IEEE J Transl Eng Health Med 2019; 7:4100209
43. DeMerle KM, Angus DC, Baillie JK, et al: Sepsis subclasses: A framework for development and interpretation. Crit Care Med 2021; 49:748–759 21. Zhang Z, Zhang G, Goyal H, et al: Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: A latent profile analysis. Crit Care 2018; 22:347
44. Bhavani SV, Semler M, Qian ET, et al: Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med 2022; 48:1582–1592
45. Seymour CW, Kennedy JN, Wang S, et al: Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA 2019; 321:2003–2017
46. Komorowski M, Celi LA, Badawi O, et al: The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care. Nat Med 2018; 24:1716–1720
47. Roggeveen L, El Hassouni A, Ahrendt J, et al: Transatlantic transferability of a new reinforcement learning model for optimizing haemodynamic treatment for critically ill patients with sepsis. Artif Intell Med 2021; 112:102003
48. Böck M, Malle J, Pasterk D, et al: Superhuman performance on sepsis MIMIC-III data by distributional reinforcement learning. PLoS One 2022; 17:e0275358
49. Wu X, Li R, He Z, et al: A value-based deep reinforcement learning model with human expertise in optimal treatment of sepsis. NPJ Digit Med 2023; 6:15
50. Joshi S, Parbhoo S, Doshi-Velez F: Learning-to-defer for sequential medical decision-making under uncertainty. arXiv:2109.06312
51. Merouani M, Guignard B, Vincent F, et al: Norepinephrine weaning in septic shock patients by closed loop control based on fuzzy logic. Crit Care 2008; 12:R155
52. Ghosh S, Li J, Cao L, et al: Septic shock prediction for ICU patients via coupled HMM walking on sequential contrast patterns. J Biomed Inform 2017; 66:19–31
53. TW, Zhang H, Subramanian J, et al: An empirical study of representation learning for reinforcement learning in healthcare. arXiv [cs.LG] Preprint posted online November 23, 2020. doi: 10.48550/arXiv.2011.11235
54. Belogolovsky S, Korsunsky P, Mannor S, et al: Inverse reinforcement learning in contextual MDPs. Mach Learn 2021; 110:2295–2334
55. Seymour CW, Liu VX, Iwashyna TJ, et al: Assessment of clinical criteria for sepsis: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315:762–774
56. Kamran F, Tjandra D, Heiler A, et al: Evaluation of sepsis prediction models before onset of treatment. NEJM AI 2024; 1 35. Johnson AEW, Pollard TJ, Shen L, et al: MIMIC-III, a freely accessible critical care database. Sci Data 2016; 3:160035
57. World Health Organization: Global Report on the Epidemiology and Burden of Sepsis: Current Evidence, Identifying Gaps and Future Directions. 2020. Available at: https://reliefweb.int/report/world/global-report-epidemiology-and-burden-sepsiscurrent-evidence-identifying-gaps-and. Accessed January 16, 2024
58. Maximous S, Brotherton BJ, Achilleos A, et al; COVID-LMIC Task Force and the Mahidol-Oxford Research Unit (MORU): Pragmatic recommendations for the management of COVID19 patients with shock in low- and middle-income countries. Am J Trop Med Hyg 2020; 104:72–86
59. Sheller MJ, Edwards B, Reina GA, et al: Federated learning in medicine: Facilitating multi-institutional collaborations without sharing patient data. Sci Rep 2020; 10:12598
60. Khan, M. I., Arif, A., & Khan, A. R. A. (2024). The Most Recent Advances and Uses of AI in Cybersecurity. *BULLET: Jurnal Multidisiplin Ilmu*, *3*(4), 566-578.
61. Gupta A, Lash MT, Nachimuthu SK: Optimal sepsis patient treatment using human-in-the-loop artificial intelligence. Expert Syst Appl 2021; 169:114476 41. Xu Y, Xiao C, and Sun J: DeepRite: Deep recurrent inverse treatment weighting for adjusting time-varying confounding in modern longitudinal observational data. ArXiv:2010.15028

BULLETIN OF INFORMATICS

BIN: Bulletin of Informatics
Volume 2, No. 2 Oktober, 2024
ISSN 3025-7417 (media online)
Hal 297 -315

62. Jeter R, Lehman L-W, Josef C, et al: Learning to treat hypotensive episodes in sepsis patients using a counterfactual reasoning framework. medRxiv 2021.03.03.21252863
63. Kausik C, Lu Y, Tan K, et al: Offline policy evaluation and optimization under confounding. arXiv:2211.16583
64. Chase JG, Preiser J-C, Dickson JL, et al: Next-generation, personalised, model-based critical care medicine: A state-of-the art review of in silico virtual patient models, methods, and cohorts, and how to validation them. Biomed Eng Online 2018; 17:24
65. Raghu A, Komorowski M, Ahmed I, et al: Deep reinforcement learning for sepsis treatment. arXiv:1711.09602
66. Bologheanu R, Kapral L, Laxar D, et al: Development of a reinforcement learning algorithm to optimize corticosteroid therapy in critically ill patients with sepsis. J Clin Med 2023; 12:1513
67. Vasey B, Nagendran M, Campbell B, et al; DECIDE-AI expert group: Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI. Nat Med 2022; 28:924–933
68. Madras D, Pitassi T, Zemel R: Predict responsibly: Improving fairness and accuracy by learning to defer. ArXiv: 1711.06664
69. Wilson FP, Martin M, Yamamoto Y, et al: Electronic health record alerts for acute kidney injury: Multicenter, randomized clinical trial. BMJ 2021; 372:m4786
70. Festor P, Jia Y, Gordon AC, et al: Assuring the safety of AI-based clinical decision support systems: A case study of the AI clinician for sepsis treatment. BMJ Health Care Inform 2022; 29:e100549
71. Nagendran M, Festor PGRE, Komorowski M, et al: Clinical Evaluation Framework Using Behavioural & Visual Attention Read-Outs for Explainable AI (XAI). 2023. Available at: https://ssrn.com/abstract=4496127. Accessed August 18, 2023
72. Sivaraman V, Bukowski LA, Levin J, et al: Ignore, trust, or negotiate: Understanding clinician acceptance of AI-based treatment recommendations in health care. Proceedings of the 2023 CHI Conference on Human Factors in Computing Systems. New York, NY, Association for Computing Machinery, 2023, pp 1–18
73. Wong A, Otles E, Donnelly JP, et al: External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med 2021; 181:1065–1070
74. Feng J, Phillips RV, Malenica I, et al: Clinical artificial intelligence quality improvement: Towards continual monitoring and updating of AI algorithms in healthcare. NPJ Digit Med 2022; 5:66
75. Henry KE, Adams R, Parent C, et al: Factors driving provider adoption of the TREWS machine learning-based early warning system and its effects on sepsis treatment timing. Nat Med 2022; 28:1447–1454